Product Overview

Ultima-Sus by Ultima Pharma USA standardizes 500mg/ml quadruple testosterone ester blend concentration within 10ml amber glass vial engineered for continental USA performance compound fulfillment. Four-ester configuration provides continuous testosterone release spanning short through ultra-long pharmacokinetic profiles from 1-21 days. Ultima Pharma channels this high-potency presentation toward procurement networks prioritizing comprehensive mass accumulation alongside weekly administration within domestic pharmaceutical logistics frameworks.​

Brand & Manufacturer Information

Ultima Pharma configures production capacity around oil-based testosterone ester blends replicating sustained-release profiles, maintaining USA operational infrastructure optimized for domestic warehouse-to-warehouse transit velocity and comprehensive batch traceability deployment. Manufacturing standardization emphasizes synchronized ester release consistency across elevated 500mg/ml threshold while integrating proprietary verification symbology. Wholesale partnerships leverage formulation fidelity metrics alongside perpetual replenishment cadence reliability critical for institutional distribution sustainability.​

Active Compound Information

Ultima-Sus systematically integrates Testosterone Propionate (70mg/ml) conferring rapid onset, Testosterone Phenylpropionate (60mg/ml) providing early-mid duration, Testosterone Isocaproate (110mg/ml) bridging intermediate phase, and Testosterone Decanoate (260mg/ml) extending ultra-long elimination to 15-21 days. Quadruple-ester architecture delivers continuous androgen receptor activation spanning complete pharmacokinetic spectrum characteristic of engineered sustained-release optimization. Blend manifests comprehensive aromatization supporting nitrogen retention, protein synthesis elevation, and red blood cell production synergy.​

Product Specifications

Injectable solution furnishes 500mg/ml total testosterone ester concentration (70mg/ml Testosterone Propionate, 60mg/ml Testosterone Phenylpropionate, 110mg/ml Testosterone Isocaproate, 260mg/ml Testosterone Decanoate) across 10ml multi-dose capacity utilizing pharmaceutical-grade carrier oil matrix with benzyl alcohol preservation. Sterile 0.22μ filtration precedes rubber-stoppered vial sealing incorporating aluminum crimp seal and flip-top security mechanism. Vial documentation enumerates precise ester ratios, aggregate potency declaration, sequential lot designation, fabrication temporal reference, and projected pharmacotherapeutic stability timeline.​

Quality Control & Testing Standards

Ultima Pharma executes multi-dimensional chromatographic profiling verifying individual ester quantitation alongside pharmacopeial sterility validation, endotoxin compliance measurement below 0.5 EU/ml, and preservative functionality per international monographs. Terminal sterile filtration integrates randomized composite sampling against parametric specifications while serialization enables recipient-independent authenticity adjudication through global verification infrastructure. Third-party certification protocols precede blend commercialization ensuring synergistic potency delivery across complete ester spectrum with full HPLC certificate availability.​

Intended Use & Market Positioning

Ultima Pharma directs Ultima-Sus 500mg/ml 10ml toward advanced clientele executing extended bulking protocols requiring single weekly injection convenience spanning multiple pharmacokinetic phases. Quadruple-ester configuration maintains continuous testosterone saturation ideal for progressive overload training phases supporting 20+ pound mass accrual. USA geolocational optimization confers dispatch velocity precedence serving credential-verified performance networks prioritizing maximal physiological augmentation precision.​

Packaging, Storage & Handling

Primary amber glass vial consolidation within protective secondary enclosure integrates dosage authentication cartography, rubber septum penetration verification indicators, flip-top intrusion detection engineering, and microenvironmental sequestration specifications for domestic transit resilience. Preservation ordinance prescribes thermal confinement 15-25°C within inverted orientation repositories mitigating sedimentation layering and oxidative degradation cascades. Protocol mandates crimp seal continuity validation and flip-top functionality confirmation preceding restricted-access conservation domain assignment.​

Purchasing & Availability Information

Ultima-Sus 500mg/ml 10ml by Ultima Pharma USA sustains perpetual standing inventory across credentialed electronic transaction architectures with redundant domestic warehouse positioning. Transaction orchestration fuses end-to-end cryptographic financial pathway processing, transit obfuscation enclosure protocols, and premium parcel acceleration networks. Institutional acquisition contingents unlock progressive volumetric economic calibration while discrete transactions receive expedited staging predicated upon eligibility parameter verification and packaging pre-authentication.​

Legal & Regulatory Disclaimer

Acquisition principals assume unqualified fiduciary accountability for statutory conformity spanning procurement entitlement, possession legitimacy, cross-jurisdictional conveyance authorization, and application permissions pursuant to controlling federal, state, municipal ordinance hierarchies. Ultima Pharma commercializes Ultima-Sus exclusively as parametrically-declared bulk active pharmaceutical matrix; no attestations encompass therapeutic protocol substitution, diagnostic adjunct deployment, prophylactic strategy implementation, or physiological trajectory forecasting. Documentation framework constitutes commercial-informational reference exclusively, expressly prohibiting interpretive counsel substitution. Transaction eligibility conditioned upon recipient compliance attestation with packaging verification; regulatory contravention nullifies manufacturer liability protections.